Masimo Corporation

Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to

Are you a current or former employee of the company?*YesNo


+Additional Purchases


+Additional Sales

If you prefer, you may submit your transaction information or comments/questions in the box below:

There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.

We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at, or by email at

If you choose to take no action, you can remain an absent class member.

Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.

The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

Portnoy Law Firm
Lesley F. Portnoy, Esq.,
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067

On July 17, 2023, medical technology company Masimo announced preliminary financial results for the second quarter of 2023, which revealed revenue figures lower than anticipated and reduced full-year revenue estimates for both its healthcare and non-healthcare segments. Consequently, Masimo’s stock price suffered a significant decline of $29.43, marking a 20% drop, and closing at $117.73 per share on July 18, 2023, resulting in financial losses for investors.

The class action complaint filed alleges that during the Class Period, the defendants engaged in making materially false or misleading statements while also omitting crucial adverse facts regarding Masimo’s business, operations, and prospects. Specifically, the complaint claims that the defendants provided a misleading impression of their knowledge about the company’s sales pipeline, failed to appropriately address the potential loss of sensor sales and a potential drop in demand for certain product categories, overlooked the decline in sales, and consequently, their positive statements regarding the company’s prospects lacked a solid foundation and were misleading.